Key Drivers
- High profitability
- Weak liquidity
- Heavy leverage
AIAI Summary
Kenvue should no longer be viewed as a defensive dividend staple but as a transition/repricing trade—operationally cash‑generative with margin upside, yet dominated by deal-driven leverage and Tylenol litigation that materially constrain flexibility and valuation. Actionable approach: avoid relying on the dividend until pro‑forma deleveraging or clearer legal outcomes, or consider opportunistic buys only after deleveraging progress or a reclaim above ~19.12 that signals sentiment reset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High profitability
- •Weak liquidity
- •Heavy leverage
Strong, durable margins and cash conversion (58% gross, 19% EBITDA, FCF $1.72B, ROIC 23%) are offset by weak short‑term liquidity, material long‑term leverage, large intangibles, and a dividend payout that exceeds annual EPS, leaving limited downside protection versus a premium valuation.
Price Behavior
Key Price Behavior Insights:
- •Below 21-day SMA
- •Support held twice
- •Lower-highs pattern
Over the last month the stock is in a short-term downtrend—closing below the ~$18.19 SMA and down ~7% from $18.72 to $17.40 while holding support at $17.35–$17.45 and facing resistance near $19.12.
Rough 7% decline from $18.72 to $17.40 over last month
Sentiment & News
Key News Insights:
- •Increased leverage
- •Tylenol litigation
- •Mixed flows
Kenvue faces heightened investor scrutiny as Kimberly‑Clark's leverage-raising deal, ongoing Tylenol litigation and reputational fallout, and mixed institutional rebalancing increase financial and legal risk.
Expect KVUE to see continued share volatility and pressure on buybacks/dividend policy until leverage and legal risks are resolved
Similar Companies in Consumer Defensive
Other companies in the same sector with AI ratings